Cognition Therapeutics wins US patent for new crystalline form of zervimesine through 2045

By Public Technologies
  • Cognition Therapeutics won a U.S. patent covering a new crystalline form of its lead candidate zervimesine (CT1812).
  • The composition-of-matter protection runs through 2045, with potential FDA-related extension of up to five years.
  • Claims also cover a manufacturing process plus treatment methods for Alzheimer’s disease, dry AMD, dementia with Lewy bodies.
  • Management plans an FDA meeting next week on registrational endpoints in dementia with Lewy bodies.
  • Manufacturing of the newly patented form is slated to start in Q1 2027 for a registrational trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130600PRIMZONEFULLFEED9844309) on October 13, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.